newsfilter
← Latest News
GlobeNewswire·

Regeneron Reports Third Quarter 2026 Financial and Operating Results

Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025Dupixent® global net sales (recorded by Sanofi) increased 35% to $6.5 billionEYLEA HD® U.S. net sales increased 62% to